Application of CDK4/6 inhibition therapies to PDACs

被引：0
|
作者：
Zhang, Yuanyuan [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Oncol & Mol Biol, Kanazawa, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3215
引用
收藏
页码：1937 / 1937
页数：1
相关论文
共 50 条
  • [31] CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
    Goel, Shom
    DeCristo, Molly J.
    McAllister, Sandra S.
    Zhao, Jean J.
    TRENDS IN CELL BIOLOGY, 2018, 28 (11) : 911 - 925
  • [32] CDK4/6 inhibition in early and metastatic breast cancer: A review
    de Groot, A. F.
    Kuijpers, C. J.
    Kroep, J. R.
    CANCER TREATMENT REVIEWS, 2017, 60 : 130 - 138
  • [33] Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
    Dean, Jeffry L.
    McClendon, A. Kathleen
    Knudsen, Erik S.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (34) : 29075 - 29087
  • [34] CDK4/6 inhibition as maintenance therapy in ovarian cancer.
    Iyengar, Mangala
    Coffman, Lan
    Buckanovich, Ronald
    CLINICAL CANCER RESEARCH, 2016, 22
  • [35] CDK4/6 inhibition in cancer: the cell cycle splicing connection
    Sheppard, Karen E.
    AbuHammad, Shatha
    MOLECULAR & CELLULAR ONCOLOGY, 2019, 6 (06)
  • [36] CDK4/6 inhibition triggers anti-tumour immunity
    Shom Goel
    Molly J. DeCristo
    April C. Watt
    Haley BrinJones
    Jaclyn Sceneay
    Ben B. Li
    Naveed Khan
    Jessalyn M. Ubellacker
    Shaozhen Xie
    Otto Metzger-Filho
    Jeremy Hoog
    Matthew J. Ellis
    Cynthia X. Ma
    Susanne Ramm
    Ian E. Krop
    Eric P. Winer
    Thomas M. Roberts
    Hye-Jung Kim
    Sandra S. McAllister
    Jean J. Zhao
    Nature, 2017, 548 : 471 - 475
  • [37] CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
    McClendon, A. Kathleen
    Dean, Jeffry L.
    Rivadeneira, Dayana B.
    Yu, Justine E.
    Reed, Christopher A.
    Gao, Erhe
    Farber, John L.
    Force, Thomas
    Koch, Walter J.
    Knudsen, Erik S.
    CELL CYCLE, 2012, 11 (14) : 2747 - 2755
  • [38] CDK4/6 inhibition and sorafenib: a menage a deux in HCC therapy?
    Calvisi, Diego
    Eferl, Robert
    GUT, 2017, 66 (07) : 1179 - 1180
  • [39] TARGETING RECURRENT IDH MUTANT GLIOMA WITH CDK4/6 INHIBITION
    Miller, Julie
    Cahill, Daniel
    Melamed, Lisa
    Nagashima, Hiroaki
    NEURO-ONCOLOGY, 2021, 23 : 175 - 175
  • [40] CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
    Elizabeth Sakach
    Merve Keskinkilic
    Sarah Wood
    Madison Canning
    Kevin Kalinsky
    Current Treatment Options in Oncology, 2023, 24 (9) : 1103 - 1119
12345